MAPT and Alzheimer disease: This is a disadvantage of using the peptide nanofibers for AD-treatment, because not only the aggregation of Aβ proteins, but also that of tau proteins should be targeted: the charged nanofibers suppress the aggregation of one protein, but promote that of the other because Aβ molecules (pI = 5.5) and 3RMBD of tau (pI = 9.6) [30, 31] have opposite net charges at neutral pH.